A Randomized, Double-blind, Placebo-controlled Phase 2 Study of MM-141 plus NabPaclitaxel and Gemcitabine versus Nab-Paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer
|Male and Female Patients
|U.S. Govt. ID:
|Gulam Manji MD: 646-317-6085 / email@example.com
This study is for patients with newly discovered metastatic pancreatic cancer. The main purpose of this study is to evaluate whether the combination of MM-141, nabpaclitaxel and gemcitabine works better against tumor cells than nab-paclitaxel and gemcitabine alone in subjects with this pancreatic cancer.
This study is closed
Gulam Manji, MD, PhD
|Do you have pancreatic cancer?